TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03261752

Intervention type: DIAGNOSTIC_TEST
Intervention: blood sample
Description: Total genomic DNA will be extracted DNA extraction kit using a QIAamp DNA Blood Mini kit .Genetic analysis of both SPG20 \&STK31 by RTPCR.

Intervention type: DIAGNOSTIC_TEST
Intervention: blood sample
Description: Total genomic DNA will be extracted DNA extraction kit using a QIAamp DNA Blood Mini kit .Genetic analysis of both SPG20 \&STK31 by RTPCR.
Study: NCT04299789

Intervention type: OTHER
Intervention: Validating the Military Service Identification Tool
Description: This study seeks to validate the Military Service Identification Tool in its ability to accurately determine military service status.

Intervention type: OTHER
Intervention: Validating the Military Service Identification Tool
Description: This study seeks to validate the Military Service Identification Tool in its ability to accurately determine military service status.
Study: NCT04530084

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OMNI Surgical System
Description: Scheduled for canaloplasty and trabeculotomy with or without cataract extraction
Study: NCT02595489

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin D3
Description: Daily oral supplement provided by study investigators
Study: NCT02449148

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Calorie Restriction
Description: diet intervention to reduce the risk for obesity associated diseases

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Calorie Restriction
Description: diet intervention to reduce the risk for obesity associated diseases
Study: NCT00753649

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix™ hexa
Description: Intramuscular, three doses

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infanrix™ hexa
Description: Intramuscular, three doses
Study: NCT05411952

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical nutrition therapy and carbohydrate counting education
Description: Children and their mothers have received family-based behavioral medical nutrition therapy and carbohydrate counting education for 6 months by trained dietitian

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical nutrition therapy and carbohydrate counting education
Description: Only children have received family-based behavioral medical nutrition therapy and carbohydrate counting education for 6 months by trained dietitian

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No intervention
Description: Control group didn't receive any intervention by trained dietitian. Furthermore they continued their routine health controls.
Study: NCT04475302

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG vaccine (Freeze-dried)
Description: single dose of BCG vaccine (Freeze-dried) manufactured by Serum Institute of India, Pune. The composition of BCG vaccine is Live, attenuated BCG (Bacillus Calmette-Guerin Strain). (Each 1 ml contains between 2 x 106 and 8 x 106 Colony Forming Units (C.F.U.) with Diluent: Sodium Chloride Injection I.P.)
Study: NCT04531930

Intervention type: PROCEDURE
Intervention: surgery
Description: Colorectal surgery, mainly total proctocolectomy.

Intervention type: PROCEDURE
Intervention: enhanced colonoscopy
Description: Colonoscopic treatment and surveillance in every 3 months.

Intervention type: OTHER
Intervention: self choosed methods
Description: A patient chooses a method for himself other than surgery.
Study: NCT02117661

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-carnitine capsules
Description: Oral

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Cellulose capsules
Description: oral
Study: NCT00967421

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ethanol
Description: BAC level 0.5 g/dL (drink + placebo pill). Drink with 2,4 grams per kilo body weight, administered orally during 60 min, administration ending 30 min prior to start of testing. Placebo pill.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethanol
Description: BAC level 1.0 g/dL (drink + placebo pill). Drink with 3,6 grams per kilo body weight, administered orally during 60 min, administration ending 30 min prior to start of testing. Placebo pill.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo drink
Description: Placebo drink containing no alcohol + placebo pill
Study: NCT04490876

Intervention type: PROCEDURE
Intervention: 3D Pars Plana Vitrectomy associated with Extensive Brilliant Blue G-Assisted ILM Peeling Method
Description: After the injection of Brilliant Blue-G (BBG) into the vitreous cavity, the epiretinal membrane (ERM) with cellular proliferation on the surface of the retina did not stain clearly, while the internal limiting membranes did stain clearly. We peeled off the internal limiting membrane (ILM) underlying the ERM using the ILM forceps for the macular area and the serrated forceps for the remaining ILM beyond the vascular arcades (Grieshaber, Alcon Laboratories, Inc., Fort Worth, Texas (Figure1) and enhanced membrane viewing with filters on the Ngenuity system. Restaining with BBG was needed and perfluorocarbon liquid PFCL was injected with a coaxial Dual Bore cannula (MedOne) to flatten the retina.
Study: NCT03200288

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HL-01: high and low molecular weight hyaluronic acid
Description: 2 ml intra-articular single injection

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 ml intra-articular single injection
Study: NCT03108469

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IONIS-PKKRx (ISIS 546254)
Description: Those randomized to IONIS-PKKRx (ISIS 546254) will receive subcutaneous injections containing 1.00 mL (200mg) of IONIS- PKKRx (ISIS 546254) weekly for weeks 1-16.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Those randomized to placebo will receive subcutaneous injections 1.00 mL (200mg) weekly for weeks 1-16.
Study: NCT04342533

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thulium fiber laser enucleation of the prostate
Description: enucleation of the BPH according to standard procedure protocol

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Holmium laser enucleation of the prostate
Description: enucleation of the BPH according to standard procedure protocol
Study: NCT04021641

Intervention type: DIAGNOSTIC_TEST
Intervention: Speech recognition in noise
Description: Measurement of speech recognition performance in noise

Intervention type: DIAGNOSTIC_TEST
Intervention: Speech recognition in noise
Description: Measurement of speech recognition performance in noise
Study: NCT03419923

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: two stage regional citrate
Description: 4% trisodium citrate was infused at the arterial bubble trap at a rate according to the blood flow(3/4 x 1.2 x blood flow)ml/h,and at the venous bubble trap at a rate according to the blood flow(1/4 x 1.2 x blood flow)ml/h.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: two stage regional citrate
Description: 4% trisodium citrate was infused at the arterial bubble trap at a rate according to the blood flow(3/4 x 1.2 x blood flow)ml/h,and at the venous bubble trap at a rate according to the blood flow(1/4 x 1.2 x blood flow)ml/h.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: one stage regional citrate
Description: 4% trisodium citrate was infused at the arterial bubble trap at a rate according to the blood flow( 1.2 x blood flow)ml/h.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: one stage regional citrate
Description: 4% trisodium citrate was infused at the arterial bubble trap at a rate according to the blood flow( 1.2 x blood flow)ml/h.
Study: NCT04539132

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ABI Wellness Program
Description: The ABI Wellness program includes a computerized task which will be completed by all participants remotely. The exercise is a sustained visual-spatial processing task of progressively increasing difficulty. Subjects are presented with an analog clock face, initially showing only one hand. The subject uses a keyboard to enter a value for the hour shown. Feedback on the computer screen indicates whether the response is correct or incorrect. If the response was incorrect, the subject continues to respond until the correct response is entered. After this, a new clock face is shown. Once subjects reach a criterion of 90% accuracy over a series of consecutive responses, an additional hand is added to the clock face. Participants will complete the program at home, online, and will be required to be present on a video call during the exercise with the other participants and research assistants. The program is 150 hours over 6 months, through twice weekly 3-hour sessions.
Study: NCT03631888

Intervention type: DIAGNOSTIC_TEST
Intervention: preoperative abdominal ultrasound examination
Description: Performing preoperative abdominal ultrasound examination in patients that will be scheduled for elective laparoscopic surgery for any gynecologic indication
Study: NCT04913935

Intervention type: DIAGNOSTIC_TEST
Intervention: Muscle-Skeleton Ultrasonography
Description: postero-anterior radiography

Intervention type: DIAGNOSTIC_TEST
Intervention: Muscle-Skeleton Ultrasonography
Description: postero-anterior radiography
Study: NCT00772317

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Intensity Focused Ultrasound
Description: High Intensity Focused Ultrasound
Study: NCT01022528

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone (0.1 mg/kg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone (0.2 mg/kg)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Study: NCT02796183

Intervention type: DRUG
Group type: OTHER
Intervention: Subconjunctival bevacizumab (Altuzan)
Description: Subconjunctival injections of Altuzan 3.75mg were applied in order to eliminate the macular edema.
Study: NCT04250909

Intervention type: DEVICE
Intervention: Passeo-18
Description: POBA

Intervention type: DEVICE
Intervention: Passeo-18 Lux
Description: DCB
Study: NCT05295069

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A nursing care program was applied for the intervention group under the guidance of Levine's conservation model.
Description: Face-to-face training and training booklets were provided in home visits. As of the fourth home visit, Pilates exercises were performed.
Study: NCT04646044

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bempegaldesleukin
Description: Administered as an intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Standard of Care Treatment for COVID-19 Infection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care
Description: Standard of Care Treatment for COVID-19 Infection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as an intravenous infusion
Study: NCT02528552

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LH80 PRO

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Device
Study: NCT02939443

Intervention type: RADIATION
Group type: OTHER
Intervention: supine- and prone-position Computed Tomography
Study: NCT05530564

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: low-pressure pneumoperitoneum
Description: insufflation of the abdomen for creation of pneumoperitoneum, pressure set points between 8 to 10 mm Hg

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard-pressure pneumoperitoneum
Description: insufflation of the abdomen for creation of pneumoperitoneum, pressure set points between 12 to 14 mm Hg
Study: NCT00220285

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zevalin (SH L 749 , BAY86-5128)
Description: 0,3mCi/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zevalin (SH L 749 , BAY86-5128)
Description: 0,4mCi/kg
Study: NCT01045837

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone and Gluten free diet
Description: Gluten free diet and Oral Prednisolone in a dose of 1 mg/ kg will be given for a period of 4 weeks, thereafter Gluten free diet alone will be continued

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Gluten free diet
Description: Only gluten free diet will be given in this group
Study: NCT00602472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: linagliptin
Description: active

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo to linagliptin 5 mg
Study: NCT01189409

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG then Senna
Description: Stepped bowel protocol with PEG for 3 weeks followed by senna for 3 weeks. Both active treatments accompanied by placebo of alternate (lactose powder).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Senna then PEG
Description: Stepped bowel protocol with senna for 3 weeks followed by PEG for 3 weeks. Both active treatments accompanied by placebo of alternate (lactose powder).
Study: NCT01938716

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 500 mg/m2 at a fixed dose rate of 10 mg/m2/min by vein for the first 5 patients during pancreatic surgery. Next 15 subsequent patients receive 750 mg/m2 by vein at a fixed dose rate of 10 mg/m2/min.
Study: NCT01981018

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Imagery-focused Cognitive Therapy (ImCT - psychotherapy based on CBT principles)
Description: ImCT Therapy is carried out by a team of 2 co-therapists and comprises of:~* Mapping: Therapists and patient collaboratively map out difficulties and pinpoint a treatment focus, with regards to imagery symptoms and anxiety co-morbidity that impact on bipolar mood instability. This leads to an individualised formulation of the patient's current problem.~* Target: Follows the rationale, timing and objectives identified collaboratively in Mapping. It is structured around imagery-based techniques, such as imagery rescripting, which are used to address problematic imagery, to promote management of mood and boost self-care. This results into the acquisition of imagery-based mood- and anxiety-regulating strategies to be integrated into the patient's already existing coping strategies.~* Consolidation: Consist of fine tuning the strategies devised during Target based on experience gained after testing them out in real life situations and includes a video blue print.
Study: NCT04163952

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Talimogene Laherparepvec
Description: Given IM
Study: NCT02289261

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Morphine, 0.02 mg/kg PCA bolus dose with 10 minutes lock-out interval

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine plus dexmedetomidine
Description: Morphine 0.02 mg/kg plus dexmedetomidine 0.1 microgram/kg PCA bolus dose with 10 minutes lock-out interval
Study: NCT03614520

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water
Description: Mineral water will be given as placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dark beer
Description: 250 mL of IPA beer (alcohol 8.5% vol)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Light Beer
Description: 250 mL of blonde ale beer (alcohol 4,5% vol)
Study: NCT02987790

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: C-reactive protein
Description: PCR assays shall be performed daily on serum obtained from blood collected for routine intensive care examinations up to 2 days after antibiotic withdrawal. In the PCR group, antibiotic suspension will be encouraged when levels of this marker are \<35mg / L (if peak PCR below 100mg / L); or reduce 50% of the highest value (if PCR peak\> 100mg / L), with a limit of seven days, if there is clinical improvement.
Study: NCT02376699

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous (IV) SEA-CD40
Description: Given intravenously; schedule is cohort-specific.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous (IV) SEA-CD40
Description: Given intravenously; schedule is cohort-specific.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous (IV) SEA-CD40
Description: Given intravenously; schedule is cohort-specific.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous (IV) SEA-CD40
Description: Given intravenously; schedule is cohort-specific.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given intravenously; schedule is cohort-specific.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given intravenously; schedule is cohort-specific.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subcutaneous (SC) SEA-CD40
Description: Given subcutaneously on Day 1 every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subcutaneous (SC) SEA-CD40
Description: Given subcutaneously on Day 1 every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000 mg/m\^2 given intravenously on Day 1, 8, and 15 of each 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: 125 mg/m\^2 given intravenously on Day 1, 8, and 15 of each 28-day cycle
Study: NCT04452084

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: HA-WBRT
Description: The accepted standard HA-WBRT doses in the control arm are 30Gy in 10 fractions.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: HA-SIB-WBRT
Description: The doses selected for experimental HA-SIB-WBRT arm are 30Gy in 10 fractions to the whole brain with 40 to 45Gy in 10 fraction SIB doses to tumours.
Study: NCT02578706

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Clopidogrel 75mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: 81 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03630445

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isomaltooligosaccharides (IMOs)
Description: Isomaltooligosaccharides (IMOs) incorporated into yogurt were tested for gastric emptying rate, glycemic response, appetitive response, and fermentability.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Xtend® sucromalt
Description: Xtend® sucromalt incorporated into yogurt was tested for gastric emptying rate, glycemic response, appetitive response, and fermentability.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combination of IMOs and Xtend® sucromalt
Description: A combination of IMOs and Xtend® sucromalt incorporated into yogurt was tested for gastric emptying rate, glycemic response, appetitive response, and fermentability.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Raw corn starch
Description: Raw corn starch incorporated into yogurt was tested for gastric emptying rate, glycemic response, appetitive response, and fermentability.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Maltodextrin
Description: Maltodextrin incorporated into yogurt was tested for gastric emptying rate, glycemic response, appetitive response, and fermentability.
Study: NCT02231905

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI-Sifrol®
Study: NCT03085264

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Health Worker
Description: Community Health Workers calls, texts and visits patient to support them in pre-established care plans as well as medication compliance/appointment attendance
Study: NCT01695304

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ceramic water filter
Description: In total, 120 households with a child 4-10 months old will receive a Cera Maji ceramic water filter for treatment of drinking water at initial entry into the study (intervention group), and 120 households with a child 4-10 months old at initial entry into the study will not receive a ceramic water filter (control group). The study duration will be 6 months. All households in the control group will receive a Cera Maji ceramic water filter when the study ends.
Study: NCT02986295

Intervention type: DEVICE
Intervention: BioMimeTM Stent, Ultimaster® Stent

Intervention type: DEVICE
Intervention: BioMimeTM Stent, Ultimaster® Stent
Study: NCT01829906

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multidisciplinary outpatient programme

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Inpatient lifestyle programme
Study: NCT00545259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AEB071
Study: NCT01512615

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Complex Cardiac rehabilitation
Description: Complex Cardiac Rehabilitation consisting of exercise training (minimum 3 times a week for a total of twelve weeks) and psychoeducational care (5 sessions over 6 months)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control group
Description: Usual care, clinical control as provided by treating heart centre
Study: NCT03423784

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HA BPX V3.3
Description: medical device containing HA

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dentinox-Gel N
Description: Anaesthetic gel
Study: NCT00055913

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT06359353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pitavastatin
Description: Pitavastatin 2 mg or 4 mg once daily~\* The dosage is determined based on cholesterol levels and the physician's decision.